Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease

NCT07013344 · tracked via the Priya Life Science Italy tracker

Sponsor

IRCCS Ospedale San Raffaele

Phase

Observational

Started

2021-09-01

Last updated

2025-06-10

Condition(s) studied

Chronic Coronary SyndromeChronic Coronary Total OcclusionCoronary Arterial Disease (CAD)Stable Chronic AnginaNT-pro-BNP

Investigational drug(s) / intervention(s)

BNP

BNP: Measurement of plasma NT-proBNP level.

Study summary

This study aim to investigate the association between plasma NT-proBNP levels and the presence, extent and severity of stenosis in patients with suspected coronary artery disease.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * patient referred for elective coronary angiography due to suspected CAD. * NT-proBNP measurement during hospitalization Exclusion Criteria: * heart failure * severe valvular disease * atrial fibrillation * severe chronic kidney disease (eGFR \< 30 mL/min) * prior coronary artery bypass grafting * age over 80 years

Primary outcome measure(s)

Association between plasma NT-proBNP levels and the presence, extension and severity of angiographic lesions in patients with suspected CAD. — Plasma NT-proBNP levels are quantified on the morning before coronary angiography. The CAD burden is independently evaluated by two experienced interventional cardiologists periprocedurally and immediately after the coronary angiography.
Plasma NT-proBNP levels are quantified on the morning before coronary angiography using a highly sensitive electrochemiluminescence immunoassay (ECLIA) method (NT-proBNP, Roche Diagnostics, Germany), employing the Roche Modular Analytics E170 immunoassay analyzer AL. The aim of this study is to explore the association between these levels and the presence (critical vs non-critical), location (prognostic vs non-prognostic), severity (\>70%, 70-99%, 100%) and extent of obstructive lesions detected in a contemporary cohort of patients undergoing coronary angiography for suspected CAD. Coronary angiograms are independently evaluated by two experienced interventional cardiologists (C.G. and C.G.) who are blinded to the NT-proBNP levels.

Trial sites (2)

Facility	City	Region	Status
IRCCS San Raffaele Hospital	Milan	Italy	Completed
IRCCS San Raffaele Hospital	Milan	Italy	Recruiting

More IRCCS Ospedale San Raffaele trials in Italy

BLANDISH (Brain, Loss of Function, Aneurism, Disease, Injury, Stroke, Hemorrhage) Recruiting

The Echodynamic Approach Recruiting

Ultrasound Measurement of Thyroid Volume in Term Newborns Starting soon

Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies Recruiting

Optimization of Heart Failure (HF) Medical Therapy After Transcatheter Valve Intervention (TVI) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) Starting soon

Other trials for the same condition

Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque Starting soon

Spectral and Ultra High Resolution CT Systems for Non-Invasive Detection of Myocardial Ischemia: Stress CT Perfusion VS. FFR-CT Starting soon

Health Improvements by Understanding the Determinants of Residual Risk in Coronary Artery Disease and New Targets for Prevention and Treatment Recruiting

Artificial Intelligence Based Timing, Infarct Size and Outcomes in Acute Coronary Occlusion Myocardial Infarction Recruiting

Derivation and Validation of the Aortic Valve Echocardiographic Calcium Score to Confirm Severe Aortic Stenosis: the Echo-AVCS Study Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07013344 on ClinicalTrials.gov ↗ ← All trials in Italy